Mutual of America Capital Management LLC Sells 281 Shares of DaVita Inc. (NYSE:DVA)

Mutual of America Capital Management LLC decreased its stake in DaVita Inc. (NYSE:DVA) by 4.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,415 shares of the company’s stock after selling 281 shares during the period. Mutual of America Capital Management LLC’s holdings in DaVita were worth $810,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in DVA. FMR LLC increased its stake in shares of DaVita by 659.9% during the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after purchasing an additional 154,061 shares during the last quarter. Glenmede Trust Co. NA grew its holdings in DaVita by 731.6% during the third quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock valued at $20,207,000 after purchasing an additional 108,446 shares during the period. JPMorgan Chase & Co. increased its position in DaVita by 17.8% in the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after buying an additional 92,014 shares during the last quarter. KBC Group NV raised its stake in shares of DaVita by 27.3% in the third quarter. KBC Group NV now owns 313,519 shares of the company’s stock valued at $51,395,000 after buying an additional 67,250 shares during the period. Finally, Strategic Financial Concepts LLC purchased a new position in shares of DaVita during the 4th quarter valued at $9,371,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Stock Performance

Shares of DVA opened at $146.73 on Monday. DaVita Inc. has a 52-week low of $125.64 and a 52-week high of $179.60. The stock’s 50-day simple moving average is $159.43 and its 200 day simple moving average is $157.95. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The stock has a market capitalization of $11.74 billion, a price-to-earnings ratio of 13.66, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Research analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on DVA shares. Cowen reissued a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research report on Friday, February 21st. Finally, Barclays lifted their target price on shares of DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $166.33.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.